Get started
Author

N. Tarazona

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
2022 · J. Pascual, G. Attard, et al. · Annals of Oncology · 762
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
2019 · N. Tarazona, F. Gimeno-Valiente, et al. · Annals of Oncology · 287
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations
2025 · V. Seguí, J.A. Carbonell-Asins, et al. · ESMO Open · 8
Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible
2022 · N. Tarazona, F. Gimeno-Valiente, et al. · ESMO Open · 6
Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer
2025 · G. Bruixola, J. Martín-Arana, et al. · ESMO Open · 4
PDF
420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients
2020 · T.V. Henriksen, N. Tarazona, et al. · Annals of Oncology · 3
Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain
2025 · Vilma Pacheco-Barcia, Berta Obispo, et al. · Clinical & Translational Oncology · 1
PDF
464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
2021 · N. Tarazona, J. Martín-Arana, et al. · Annals of Oncology · 1
ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
2026 · N. Tarazona, A. Parikh · Annals of Oncology
P3.03.45 KRAS Mutations Shape an Oxidative, Immune-Cold Tumor Microenvironment Driving Chemo-Immunotherapy Resistance in Advanced NSCLC
2025 · V. Seguí, R. Herrero, et al. · Journal of Thoracic Oncology
406MO Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
2020 · N. Tarazona, J. Martín-Arana, et al. · Annals of Oncology
PDF
1201P The role of a mini tumour mutational burden (TMB) score generated with a customized NGS panel to predict benefit from immunotherapy
2020 · P. Lombardi, V. Gambardella, et al. · Annals of Oncology
Works count: 12
Citation count: 1,071
H-index: 4
I10-index: 2
Year
Topic
Type